Navigation Links
CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS

eutics. The Company owns three clinical-stage compounds based on its small molecule "molecular chaperone" co-induction technology. In September 2006, CytRx announced that arimoclomol was shown to be safe and well tolerated at all three doses tested in its Phase IIa clinical trial in patients with ALS. The Company plans to enter a Phase IIb clinical trial with arimoclomol in ALS in the second half of 2007, subject to FDA clearance. Based on preliminary discussions with the FDA, CytRx is now considering a second efficacy clinical trial for ALS, possibly in parallel with the upcoming Phase IIb trial, to provide additional efficacy data to support a possible approval decision by the FDA.

The FDA has granted Fast Track designation and Orphan Drug status to arimoclomol for the treatment of ALS, which has also been granted orphan medicinal product status for the treatment of ALS by the European Commission. The Company has announced plans to commence a Phase II clinical trial for arimoclomol in stroke recovery in the first half of 2008, subject to FDA clearance. The Company has also announced plans to commence a Phase II clinical trial with its next drug candidate, iroxanadine, for diabetic foot ulcers in the first half of 2008, subject to FDA clearance. In addition, the Company plans to open a research and development facility in San Diego in the third quarter of 2007. For more information on the Company, visit www.cytrx.com.

About RXi Pharmaceuticals Corporation

Worcester, Massachusetts-based RXi Pharmaceuticals Corporation, a majority-owned subsidiary of CytRx, is a biopharmaceutical research and development company that focuses on developing RNAi-based therapeutics for the treatment of human disease. RXi's initial focus is on neurodegenerative diseases, oncology, type 2 diabetes and obesity. RXi has licenses to a diverse series of early patents and patent applications that were filed from 1998 to 2006 in the areas of RNAi target sequences, RNAi chem
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
2. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
3. CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:7/28/2014)... 28, 2014  A prospective study conducted by ... has validated the performance of VolparaDensity breast ... associated volumetrically assessed breast density measurements to breast ... & Prevention (DOI: 10.1158/1055-9965.EPI-13-1219), the article, "Automated ... widespread breast cancer risk assessment," was authored by ...
(Date:7/28/2014)... , July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... company, announced today that its new PicoWay® device has ... types and colors and pigmented lesions on any skin ... device, with 532nm and 1064nm wavelengths, which utilizes Syneron,s ... using pulses which are trillionths of a second, known ...
(Date:7/28/2014)... ResMed (NYSE: RMD ), innovatore e pioniere ... respiratori del sonno (SDB) e altre patologie croniche del ... il produttore Taiwanese di dispositivi medicali, APEX Medical Corp. ... in testa, che violano i brevetti, utilizzate con l,APEX ... Corte Regionale Distrettuale di Monaco , ...
Breaking Medicine Technology:Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4ResMed riceve un'ingiunzione permanente contro APEX in Germania, continua a far valere i propri diritti per i brevetti in Europa 2
... Calif., April 2, 2012 No matter the advances that ... are suffering with tooth damage and decay every single day. According ... percent of all adults as well as 16 percent of ... the integrity and appearance of smiles, the most trusted ...
... Calif., April 2, 2012 Fortis Healthcare, ... hospitals across the country, and Masimo (NASDAQ: ... technology supplier agreement that allows Fortis hospitals access to ... pulse oximetry and noninvasive, continuous patient monitoring solutions. ...
Cached Medicine Technology:Northridge Cosmetic Dentists, Dr. Michel Elyson and Dr. Ramin Assili, are Now Offering Advanced Tooth Colored Restorations to Restore Smiles 2Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 2Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 3Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 4Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 5Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 6Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 7Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 8
(Date:7/28/2014)... The report, “Blowing Agents Market by ... and Forecasts to 2019” defines and segments the ... of the global consumption volume and value. , ... 39 figures spread through 226 Pages and in-depth ... , Blowing agents are highly utilized materials as ...
(Date:7/28/2014)... for patients with one of the UK,s most common ... Chronic obstructive pulmonary disease (COPD) is the name for ... to long-term damage to the lungs. Often linked ... of all hospital admissions in the UK, with a ... they are discharged. , A team of ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Drorit Silverman, ... unveiled new plans to raise investment capital through her ... fitness concept in the United States. , According to ... of 24/7 fitness centers provide a great window of ... rapidly expanding space. In addition to this, Silverman looks ...
(Date:7/28/2014)... -- Researchers from The University of Texas Health Science Center ... have identified a combination of pills that cures 9 of ... sofosbuvir and simeprevir, with or without ribavirin, cured 93 percent ... patients, according to the study published today in The ... U.S. , Eric Lawitz, M.D., clinical professor in the ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 The North America ... & antioxidants market in North America with analysis and forecast ... $539.9 million in 2012 to $812.7 million by 2018, at ... through the TOC of the North America Carotenoids & Antioxidants ... provided. It also provides a glimpse of the segmentation in ...
Breaking Medicine News(10 mins):Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 3Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 4Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:New pill regimens published in The Lancet cure hardest-to-treat hepatitis C patients 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4
... of Pharmaceutical Marketing Industry Due to New PhRMA ... 6 Pharmaceutical marketers are taking on the ... Systems, a unique marketing company whose integrated engagement ... the sector. In the past two years the ...
... A survey recently conducted by the Society of ... Compliance Association (HCCA) reveals that the declining economy may ... in business. In addition, this increased risk is ... risks are expected to at best hold steady, if ...
... /PRNewswire/ -- Akerman Senterfitt, one of the ... top 100 firms in the U.S., today announced that ... the auspices of the American Health Lawyers Association (AHLA) ... and issues concerning privilege and confidentiality. The live audiocast ...
... POINT, N.Y., Jan. 6 Akrimax Pharmaceuticals, LLC ... of pharmaceutical products for a global company beginning ... partners in a competitive process.Akrimax President Alan L. ... to acquire the Rouses Point facility which possesses ...
... KENILWORTH, N.J., Jan. 6 Schering-Plough Corporation (NYSE: ... results for the 2008 fourth quarter and full year on ... that day, Schering-Plough will conduct a conference call to review ... Fred Hassan, Schering-Plough,s chairman and CEO, and other members of ...
... for expanding role of patient flow automation PITTSBURGH, Jan. ... its clients, now more than 700 hospitals, solve their ... to increase capacity and improve patient flow is now ... have postponed building and expansion plans because of the ...
Cached Medicine News:Health News:Kyp Systems Takes on the Challenge of New Pharmaceutical Marketing Guidelines 2Health News:Kyp Systems Takes on the Challenge of New Pharmaceutical Marketing Guidelines 3Health News:Legal and Ethical Violations Risks Seen Rising, But Not Resources to Control the Risk 2Health News:Legal and Ethical Violations Risks Seen Rising, But Not Resources to Control the Risk 3Health News:Akerman Senterfitt Hosts National Panel Discussion on Patient Safety Organizations 2Health News:Akerman Senterfitt Hosts National Panel Discussion on Patient Safety Organizations 3Health News:Akrimax Pharmaceuticals Announces Manufacturing Partnership 2Health News:Schering-Plough Schedules Conference Call and Webcast for 2008 Fourth Quarter and Full Year Earnings 2Health News:TeleTracking Technologies to Focus on Growth 2Health News:TeleTracking Technologies to Focus on Growth 3
... The Premier 12 Holter Analysis Kit incorporates ... Dispersion with other powerful DMS Holter analysis ... TWA analysis possible in less than 10 ... TWA, for visual verification and validation. The ...
Velcro® Tracheostomy tube holders are available in Adult, pediatric, and infant sizes....
... be more comfortable, and you will too., ... secure and to avoid the knotty problems ... twill ties, consider the Dale® Tracheostomy Tube ... the narrow fastener tabs of the Dale® ...
... more comfortable, and you will too., ... and to avoid the knotty problems associated ... ties, consider the Dale® Tracheostomy Tube Holder. ... narrow fastener tabs of the Dale® Tracheostomy ...
Medicine Products: